Editorial: Infliximab induction therapy in pediatric Crohn's disease—A cost‐effective strategy?

LINKED CONTENT This article is linked to Vuijk et al papers. To view these articles, visit https://doi.org/10.1111/apt.18000 and https://doi.org/10.1111/apt.18053